1. Home
  2. NWTG vs MBIO Comparison

NWTG vs MBIO Comparison

Compare NWTG & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Newton Golf Company Inc.

NWTG

Newton Golf Company Inc.

HOLD

Current Price

$1.27

Market Cap

4.8M

ML Signal

HOLD

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.51

Market Cap

4.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NWTG
MBIO
Founded
2018
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8M
4.1M
IPO Year
2022
2023

Fundamental Metrics

Financial Performance
Metric
NWTG
MBIO
Price
$1.27
$0.51
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
28.8K
19.4K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
99.09
98.99
EPS
N/A
N/A
Revenue
$8,135,000.00
N/A
Revenue This Year
$53.21
N/A
Revenue Next Year
$40.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
136.14
N/A
52 Week Low
$0.70
$0.52
52 Week High
$2.07
$1.84

Technical Indicators

Market Signals
Indicator
NWTG
MBIO
Relative Strength Index (RSI) 48.93 35.11
Support Level $0.95 N/A
Resistance Level $1.79 $0.66
Average True Range (ATR) 0.08 0.02
MACD -0.01 -0.00
Stochastic Oscillator 25.00 0.00

Price Performance

Historical Comparison
NWTG
MBIO

About NWTG Newton Golf Company Inc.

Newton Golf Co Inc is a technology-forward golf company engaged in designing, manufacturing, and selling performance golf equipment, including premium golf shafts and putters, and focuses on developing technology-driven golf products intended to enhance player performance. The company sells its products through e-commerce, distributors, wholesale customers, including pro-shops at golf courses and off-course retailers, sporting goods retailers, online retailers, third-party distributors, and through Club Champion Golf.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: